This transcription factor exhibits seemingly contradictory effects in different cancers, since RUNX1 has been implicated as a tumor suppressor gene in solid tumors (e.g., breast and gastric cancer) [12, 13], while it functions as an oncogene in colorectal, ovarian, head and neck cancers [10]. This evidence concerns the gene RUNX1 and neoplasm.